#USA #New York #SueWallSt #Immutep Limited #IMMP

Immutep Limited Investors Alerted to Class Action Lawsuit

In a significant development that has captured the attention of investors, SueWallSt has issued an alert for shareholders of Immutep Limited (NASDAQ: IMMP). Investors who acquired shares between March 24, 2025, and March 12, 2026, may have suffered substantial losses and are encouraged to get in touch with the legal firm to guide them through the potential recovery of damages.

Background of the Situation

On March 13, 2026, Immutep's shares plummeted approximately 83%, dropping from $2.76 to $0.48 per share. The sharp decline was triggered by the company's announcement that the pivotal TACTI-004 Phase III clinical trial had been discontinued due to futility, leaving investors in shock.
The company had previously portrayed the trial as a major milestone, claiming strong safety and efficacy data while actively enrolling patients across numerous global sites. However, questions have been raised about whether shareholders received timely and accurate information about the risks associated with the trial.

Detailed Timeline of Events

The lawsuit highlights a chronology of key events leading to the abrupt decline in stock value:

• - March 24, 2025: Immutep announced the first patient enrolled in the TACTI-004 trial and touted the trial's significance. The company expressed confidence in the efficacy of its product, efti, while aiming to enroll approximately 756 patients.
• - April to July 2025: Subsequent quarterly updates reassured investors of the trial's steady progress and operational efforts, reinforcing the belief in its success.
• - October 9, 2025: The company reached a milestone of over 170 patients for an independent analysis, again painting a picture of continued progress for the trial.
• - Early 2026: Enrollment surged, and leadership reiterated its confidence in trial outcomes, stating that the trial was on pace and accumulating crucial data.
• - March 13, 2026: The Independent Data Monitoring Committee made the critical recommendation to halt the trial, revealing that internal analyses suggested a higher-than-expected risk of failure, leading to the catastrophic stock drop.

Legal Implications and Next Steps

The implications for investors are significant. Those who were misled during this period may be entitled to recover their losses. Joseph E. Levi, Esq., representing the firm, emphasized the importance of timely disclosures and stated that the chronology of events raised serious concerns regarding shareholder communication.

Investor Guidance

Here are some immediate steps for affected IMMP shareholders:
1. Document Your Transactions: Gather all brokerage records, including purchase dates, the quantity of shares purchased, and the prices paid. This documentation is essential for any legal proceedings.
2. Contact Legal Assistance: Interested shareholders should reach out to SueWallSt for a free evaluation of their eligibility to participate in the potential lawsuit against Immutep. If you believe you have a claim, you can reach out at [email protected] or call (888) SueWallSt.
3. Be Aware of Deadlines: The window for potential lead plaintiff applications closes on July 6, 2026. However, shareholders who miss this deadline can still partake in any settlements or recoveries that may be granted.

Conclusion

This situation serves as a cautionary tale about the risks inherent in investing, especially with companies involved in clinical trials. It underscores the necessity of thorough due diligence and staying informed about the progress of investments. Investors are strongly encouraged to seek legal counsel to navigate this challenging landscape and to explore their rights regarding potential recovery of losses due to alleged misinformation from Immutep Limited.

For those affected, understanding your rights in this complex landscape is essential. Do not hesitate to act swiftly — the potential for recovery may be just a consultation away.